Case Reports in Oncological Medicine最新文献

{"title":"Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation.","authors":"Bana Antonios, Oyepeju Abioye, Seon Jo Park, Gene Finley","doi":"10.1155/crom/7966703","DOIUrl":"10.1155/crom/7966703","url":null,"abstract":"<p><p>Endometrial carcinoma (EC) is a heterogeneous malignancy with diverse molecular subtypes that influence prognosis and treatment response. While conventional therapies such as surgery, chemotherapy, and radiation remain the mainstay of treatment, recurrent and metastatic EC poses significant therapeutic challenges, particularly in aggressive histologic subtypes like clear cell carcinoma. Advances in genomic profiling have revealed that KRAS mutations occur in approximately 10%-30% of EC cases, with the KRAS G12C variant representing a rare but potentially targetable alteration. KRAS G12C inhibitors, including sotorasib and adagrasib, have revolutionized the treatment landscape for certain malignancies, particularly non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), where they have received FDA approval. The efficacy of these agents in other KRAS G12C-mutated solid tumors remains under investigation, with limited clinical data available in endometrial cancer. To date, only three documented cases have reported responses to KRAS G12C inhibitors in EC, highlighting the need for further exploration of targeted strategies in this setting. Here, we present a unique case of a 77-year-old woman with metastatic endometrial clear cell carcinoma who exhibited a durable response to adagrasib after progressing on multiple lines of standard treatment. This case highlights the potential clinical utility of KRAS G12C inhibitors in EC and highlights the importance of molecular profiling in identifying actionable mutations that may guide treatment decisions. This report, contributing to the limited body of evidence that includes three prior cases evaluating the role of sotorasib and adagrasib across several solid malignancies, highlights the clinical and translational relevance of adagrasib in advancing precision-targeted therapy for KRAS G12C-mutated tumors.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"7966703"},"PeriodicalIF":0.6,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12680454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple-Negative Male Breast Cancer Presenting as Cutaneous Metastasis: A Diagnostic Rarity.","authors":"Saran Lal Ajai Mokan Dasan, Neelanjana Pandey, Mikhail Sukhoroslov, Donald Rudikoff, Naqash Mazhar","doi":"10.1155/crom/4393243","DOIUrl":"10.1155/crom/4393243","url":null,"abstract":"<p><p>Cancer of the male breast is a rare disease. It comprises less than 1% of all breast carcinomas and less than 1.5% of all malignant tumors in men. Male breast cancer presenting as skin metastasis is exceptionally uncommon. A review of the medical literature identified only a handful of such cases. We present a malignant axillary skin tumor with multiple visceral metastases originating from a breast primary. Although often grouped together, recent evidence indicates that male breast cancer is a distinct tumor on both genetic and molecular grounds when compared to the significantly more prevalent female breast cancer. Since new details and treatment strategies are emerging for male breast cancer, we wish to highlight a rather unusual presentation of this often-overlooked cancer. Skin metastasis is generally detected at the terminal stage of the malignancy. In our patient, however, the skin metastasis initiated the diagnostic workup.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"4393243"},"PeriodicalIF":0.6,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12660637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary High-Grade Ovarian Sertoli-Leydig Cell Tumor With Bilateral Adnexal Involvement in a Patient Diagnosed With Peutz-Jeghers Syndrome.","authors":"Tuba Bozhuyuk Sahin, Bayram Burak Ceviz, Ozge Ozmen, Gulay Turan, Figen Efe Camili, Gurhan Guney, Mine Islimye Taskin, Selim Afsar","doi":"10.1155/crom/3815492","DOIUrl":"https://doi.org/10.1155/crom/3815492","url":null,"abstract":"<p><strong>Aim: </strong>Peutz-Jeghers syndrome is a rare genetic disease with an increased risk of gastrointestinal and extragastrointestinal malignancies. Ovarian involvement of Sertoli-Leydig cell tumors is uncommon and even more rare in Peutz-Jeghers syndrome patients. This case report outlines the importance of primary ovarian Sertoli-Leydig cell tumor with bilateral adnexal involvement in a patient diagnosed with Peutz-Jeghers syndrome.</p><p><strong>Case: </strong>A 31-year-old female patient diagnosed with Peutz-Jeghers syndrome presented to our clinic with pelvic pain. Ultrasound examination revealed solid masses in both adnexa. Laparoscopic fertility-preserving surgery was performed. Pathology confirmed the diagnosis of poorly differentiated solid ovarian Sertoli-Leydig cell tumor. Staging surgery was performed, and finally, the patient was referred to oncology for chemotherapy.</p><p><strong>Conclusion: </strong>This case report outlines the importance of Sertoli-Leydig cell tumors in the differential diagnosis of adnexal masses in patients with Peutz-Jeghers syndrome. Bilateral adnexal involvement is an unusual presentation of Sertoli-Leydig cell tumors. Despite unusual and different presentations, Sertoli-Leydig cell tumors should not be ignored or overlooked in patients with Peutz-Jeghers syndrome.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"3815492"},"PeriodicalIF":0.6,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12657083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145629955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintenance of a High Quality of Life of a Pancreatic Cancer Patient in a Multidisciplinary Care Center: A Case Report.","authors":"Takayoshi Ubuka, Keiko Kato, Takeshi Hirose, Ken Sugimoto, Yoichi Yamane","doi":"10.1155/crom/1775859","DOIUrl":"https://doi.org/10.1155/crom/1775859","url":null,"abstract":"<p><strong>Introduction: </strong>The symptom and treatment of pancreatic ductal adenocarcinoma (PDA) at an advanced stage significantly deteriorate patients' quality of life (QOL). Therefore, multidisciplinary long-term and palliative care is needed to maintain patients' physical, social, and psychological well-being and ultimately improve survival.</p><p><strong>Case presentation: </strong>An octogenarian residing in a care center, which can provide multidisciplinary long-term care with nutritional, physical, and social support, as well as pain management through home medical services, was diagnosed with Stage IV PDA. She received multiple outpatient chemotherapy sessions and experienced cancer-related pain and fatigue. However, participating in individual functional training and altruistic social activities at the day service center, which is a crucial component of Japan's long-term care system, within the care center maintained her high level of QOL for 5 years and 5 months until she died peacefully at the care center.</p><p><strong>Conclusion: </strong>Multidisciplinary care with nutritional support, palliative care, exercise, and social support at the care center may have reduced the patient's psychological stress and maintained her physical and psychological well-being and ultimately improved her QOL and survival. The multidisciplinary care center may be a candidate for a new model system of palliative and hospice care that did not only provide pain/symptom control and terminal care but also maintained a high QOL of the patient.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"1775859"},"PeriodicalIF":0.6,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12646733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145629908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive Therapeutic Monitoring of Circulating Tumor DNA in BRAF-Mutant Metastatic Colon Cancer Using Droplet Digital PCR, Next-Generation Sequencing, and Fragmentomics.","authors":"Rachel C T Lam, Connie W C Hui, Irene O L Tse, Qing Zhou, Chit Chow, Wei Kang, K C Allen Chan, Brigette B Y Ma, W K Jacky Lam","doi":"10.1155/crom/8140524","DOIUrl":"10.1155/crom/8140524","url":null,"abstract":"<p><strong>Purpose: </strong><i>BRAFV600E</i>-mutated metastatic colorectal cancers (mCRCs) are associated with poorer prognosis. We present a case, in which noninvasive therapeutic monitoring was performed on a patient with <i>BRAF</i>-mutant mCRC, aiming to track disease progression and elucidate the mechanisms of response and resistance towards anti-<i>BRAF</i> therapy.</p><p><strong>Methods: </strong>A 40-year-old man diagnosed with metastatic <i>BRAFV600E</i> mutant sigmoid adenocarcinoma received multiple lines of treatment, including first-line chemotherapy + bevacizumab and targeted therapy of cetuximab, encorafenib ± binimetinib. Noninvasive therapeutic monitoring was performed on ctDNA using our in-house designed droplet digital PCR assay and fragmentomics. We also performed serial and paired analyses of tissue, liquid biopsy, and in vitro studies at different multiple timepoints.</p><p><strong>Results: </strong>ctDNA and fragmentomics biomarkers were concordant with, and even preceded traditional serological and radiological biomarkers in predicting disease progression. Molecular analyses and drug testing also revealed mutations that are either potentially targetable or account for resistance, which guided the subsequent treatment regimen.</p><p><strong>Conclusion: </strong>This case demonstrates the potential application of ctDNA and fragmentomics biomarkers, molecular analyses, and drug testing in noninvasive therapeutic monitoring of <i>BRAFV600E</i> mutant mCRC. These illustrate the potential application of such noninvasive therapeutic monitoring in larger scale cohorts of patients.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"8140524"},"PeriodicalIF":0.6,"publicationDate":"2025-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lutetium-177 DOTATATE for the Treatment of Esthesioneuroblastoma: A Case Report.","authors":"Vaneza Avila-Rodriguez, Nicolle Wagner-Gutiérrez, Javier Jacobo, Diego Pineda, Alejandro Gonzalez, Jorge Aristizabal, Ivan Bobadilla, Natalia Sánchez, Jairo A Zuluaga, Andrés F Cardona","doi":"10.1155/crom/5563379","DOIUrl":"10.1155/crom/5563379","url":null,"abstract":"<p><p>Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare neuroendocrine malignancy arising from the olfactory neuroepithelium. It exhibits a wide range of biological behaviors, from indolent to highly aggressive disease, often requiring a multimodal treatment approach involving surgical resection, radiotherapy, and chemotherapy, though outcomes remain variable. The overexpression of somatostatin receptors (SSTRs), particularly SSTR2, has led to the exploration of peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (Lu-177) as a targeted option in refractory cases. We present the case of a 64-year-old woman with recurrent, metastatic ENB, Kadish Stage D (T2N0M0G2). After undergoing surgical resection, intensity-modulated radiotherapy (IMRT), and systemic chemotherapy (cisplatin/etoposide), the patient experienced disease progression, prompting the initiation of targeted therapy with sunitinib. Given high SSTR expression detected on Gallium-68 PET imaging, four cycles of PRRT with Lu-177 DOTATATE were introduced with adverse effects (Grade 1 fatigue, nausea, leukopenia, anemia, and thrombocytopenia). While initial tumor regression was observed, subsequent progression necessitated further stereotactic body radiotherapy (SBRT) and temozolomide. This case highlights the therapeutic potential of PRRT with Lu-177 DOTATATE in treating refractory SSTR-expressing ENB. A multidisciplinary approach that integrates surgery, radiotherapy, systemic therapy, and theragnostic strategies remains essential to optimizing patient outcomes.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5563379"},"PeriodicalIF":0.6,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12615023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancytopenia With Subsequent Diagnosis of Hemophagocytic Lymphohistiocytosis in a Middle-Aged Male.","authors":"Pavel Bleik, Steve Nwokeocha, Thanmay Sathi, Egor Zakharchenko, Day Hills","doi":"10.1155/crom/5526211","DOIUrl":"10.1155/crom/5526211","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome resulting from uncontrolled activation of the immune system. It is characterized by persistent fever, cytopenias, organomegaly, and a constellation of laboratory abnormalities including hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, and elevated soluble interleukin-2 receptor levels. HLH can be broadly classified into primary (familial) and secondary forms, the latter often triggered by infections, malignancies, autoimmune diseases, or other systemic insults. Despite advancements in diagnostic criteria and therapeutic strategies, HLH continues to carry high morbidity and mortality, largely due to its nonspecific and variable presentation that often leads to delays in diagnosis. Early recognition and prompt initiation of immunosuppressive therapy are crucial to improving outcomes. We are presenting a case of symptomatically gastrointestinal-dominant HLH presentation potentially due to an unusual trigger of TMP/SMX in an otherwise healthy adult male who presented with flu-like symptoms accompanied with abdominal pain.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5526211"},"PeriodicalIF":0.6,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12595237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct Presentations of Langerhans Cell Histiocytosis in Children: A Case Series.","authors":"Gashaw Arega, Kirubel Asmelash, Michael A Negussie, Abebe Mekonnen","doi":"10.1155/crom/5583430","DOIUrl":"10.1155/crom/5583430","url":null,"abstract":"<p><p>Langerhans cell histiocytosis (LCH) is a rare pediatric histiocytic disorder characterized by diverse clinical manifestations, ranging from isolated lesions to severe multisystem involvement. This case series presents three distinct presentations observed in children. The first case involved a 4-year-old female presenting with generalized lymphadenopathy, polyuria, polydipsia, bilateral vision loss, and systemic symptoms, indicative of significant pituitary and multisystem involvement. Imaging revealed lesions involving the pituitary gland, hypothalamus, and sphenoid sinus. The second case described a 10-year-old male experiencing respiratory distress, significant weight loss, polyuria, and multiple lytic bone lesions. Diagnostic imaging identified extensive colonic involvement, bilateral hydronephrosis, and pulmonary lesions, emphasizing unusual systemic features. The third patient, an 18-month-old child, initially presented with persistent respiratory symptoms, a diffuse rash, severe acute malnutrition, and hepatomegaly and was initially misdiagnosed as having tuberculosis. Later imaging studies revealed extensive pulmonary cystic lesions. Immunohistochemistry from the tissue biopsy demonstrated CD1a positivity, confirming LCH diagnoses. Treatment strategies included standard induction protocols with vinblastine and corticosteroids. These cases show how LCH can present in many different ways in pediatric patients, often in unexpected patterns. Early recognition, thorough imaging, and histological confirmation are crucial for accurate diagnosis. Being aware of the wide range of symptoms can help ensure prompt treatment and better outcomes for this serious but manageable condition.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5583430"},"PeriodicalIF":0.6,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12591817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank.","authors":"Mohammed B Abboushi, Omar Marouf, Mohammed AbuBaha, Hossam Salameh, Ro'ya Soradi, Riad Ahmad Amer","doi":"10.1155/crom/4802098","DOIUrl":"10.1155/crom/4802098","url":null,"abstract":"<p><strong>Background: </strong>Classical Hodgkin lymphoma (cHL) is a highly curable B-cell malignancy; though, rarely, it can transform into non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, or marginal zone lymphoma. Reports of such transformations remain limited in the literature.</p><p><strong>Objective: </strong>The aim of this study is to describe the clinical course, histopathological findings, and outcomes of three patients with cHL who developed secondary NHL.</p><p><strong>Results: </strong>Case 1 involved transformation from cHL to CD20+/CD30+ DLBCL following multiple lines of chemotherapy and autologous stem cell transplant, eventually resulting in progressive disease and death. Case 2 transformed into follicular lymphoma Grade 3a more than a year after cHL remission, with marrow infiltration managed conservatively pending systemic therapy. Case 3 presented with composite lymphoma at diagnosis (cHL and extranodal marginal zone lymphoma) and experienced indolent but recurrent disease involving the liver, requiring multiple rounds of chemoimmunotherapy.</p><p><strong>Conclusion: </strong>Transformation of cHL into NHL, though rare, may occur years after initial treatment or concurrently at presentation. These cases underscore the importance of repeat biopsy in suspected relapses and highlight the clinical and pathological heterogeneity of such transformations. Our paper adds to the limited literature on this phenomenon and is the first of its kind reported from Palestine.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"4802098"},"PeriodicalIF":0.6,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12588754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Case of Collecting Duct Carcinoma With Complete Response to Nivolumab.","authors":"Muhammed Hajmusa, Gi Eun Kim, Mohammed Ussama Al Homsi, Ahmed Abdalhadi","doi":"10.1155/crom/9619945","DOIUrl":"10.1155/crom/9619945","url":null,"abstract":"<p><p>Collecting duct carcinoma (CDC) is a rare, aggressive subtype of renal cell carcinoma originating in the renal medulla. We report a unique case of metastatic CDC in a patient with prior breast ductal carcinoma in situ. Genomic profiling revealed a homozygous deletion of CDKN2A (encoding p16). After progression on systemic therapies, the patient received stereotactic body radiotherapy (SBRT) to metastatic lesions concurrently with nivolumab (anti-PD-1). This regimen achieved a rapid complete radiographic remission of all lesions. We present a 63-year-old Sudanese woman with metastatic CDC who achieved a complete remission of over 5 years following nivolumab therapy. The patient initially presented with right flank pain and hematuria. Imaging revealed an exophytic renal mass, and she underwent radical nephrectomy in June 2019. Pathology confirmed high-grade CDC (pT3aN1) with clear margins; immunohistochemistry was notable for positive vimentin, PAX8, CK19, and patchy AMACR, with loss of CDKN2A. Postoperative PET/CT was clear, but by October 2019, three intra-abdominal metastases were seen (liver and retroperitoneum). She was first treated with palbociclib and letrozole, but progression occurred after 3 months. Given reports of immunotherapy efficacy in CDC, she began nivolumab in May 2020. Imaging in October 2020 showed marked tumor regression, sustained on repeat scans. In September 2021, isolated para-aortic lymph node recurrence was treated with stereotactic radiation (20-25 Gy/5 fractions) while continuing nivolumab. Subsequent PET/CT scans (Feb 2022, Feb 2023, June 2023, March 2024, and January 2025) demonstrated continued complete metabolic response. This combined modality approach achieved an unprecedented durable response, underscoring that personalized multimodal therapy-linking radiotherapy, immunotherapy and targeted cell-cycle inhibition-can yield long-term control in CDC. For a disease as lethal as CDC, this outcome demonstrates that genomically informed therapy can achieve extraordinary benefit.</p>","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"9619945"},"PeriodicalIF":0.6,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12585813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}